- Crystal Holding, an "AI pharmaceutical star" in Hong Kong, reported a significant turnaround in 2025 with a revenue of 802 million CNY, a 201.2% increase year-on-year, and a net profit of 124 million CNY, reversing a loss of 1.517 billion CNY in 2024.
- The primary driver of revenue was the core business segment "drug discovery solutions," which generated 538 million CNY—an astonishing 418.9% growth—mainly due to a key collaboration with DoveTree in multiple drug development projects.
- Crystal Holding also benefitted from other income, totaling 514 million CNY, significantly impacting profitability and easing the burden of prior financial losses.
